FDA approved Eli Lilly’s Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, extending the drug’s label beyond glucose lowering, weight loss, and glycemic control. The approval is supported by results from SURPASS-CVOT, a cardiovascular outcomes trial comparing tirzepatide head-to-head with dulaglutide (Trulicity) rather than against placebo. Across more than 13,000 participants enrolled in 30 countries, Mounjaro met the trial’s non-inferiority framework, with an estimated hazard ratio of 0.92 (95.3% CI: 0.83–1.01) for the first occurrence of MACE-3 (cardiovascular death, heart attack, or stroke). Lilly also reported gastrointestinal adverse events as the most common treatment-related events, generally mild to moderate and concentrated around dose escalation. The approval places tirzepatide directly into the cardiovascular-risk treatment conversation, strengthening its competitive position among GLP-1 and GIP class therapies that have already established outcomes benefits. It also signals continued regulatory emphasis on hard clinical endpoints for metabolic drugs.